P10 (PX)
(Delayed Data from NYSE)
$10.13 USD
+0.02 (0.20%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $10.14 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.13 USD
+0.02 (0.20%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $10.14 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Praxair's Yara Freeport Contract to Boost Hydrogen Business
by Zacks Equity Research
Praxair's (PX) long-term supply agreement with Yara Freeport LLC is to solidify its businesses, especially of the hydrogen unit, in Texas.
Here's Why You Should Add Praxair (PX) to Your Portfolio
by Zacks Equity Research
Praxair (PX) stands to gain from a solid product portfolio and increasing applications of industrial gases. Returning value to shareholders is a priority.
Watch These ETFs as Trade War Risks Rise
by Zacks Equity Research
Donald Trump announced plans to impose tariffs on Steel and Aluminum imports.
Why Is Praxair (PX) Down 4.7% Since its Last Earnings Report?
by Zacks Equity Research
Praxair (PX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Lies Ahead for Materials ETFs?
by Zacks Equity Research
China threatens to retaliate if the United States moves ahead with tariffs on metal imports.
Monsanto Battles Market Rivalry on Innovation & Bayer's Deal
by Zacks Equity Research
Monsanto Company's (MON) performance to be driven by stronger innovation and Bayer AG's pending buyout deal. However, stiff business rivalry and rising debt remain causes of concern.
Top Analyst Reports for Johnson & Johnson, Illinois Tool Works & BNY Mellon
by Mark Vickery
Today's Research Daily features new research reports on 14 major stocks, including Johnson & Johnson (JNJ), Illinois Tool Works (ITW) and Bank of New York Mellon (BK).
Praxair (PX) Tops Q4 Earnings, Linde Merger to Close in 2H18
by Zacks Equity Research
Praxair's (PX) fourth-quarter 2017 adjusted earnings benefit from solid segmental performance, partially offset by rise in costs and expenses.
Praxair Inc. (PX) Beats Q4 Earnings and Revenues
by Zacks Equity Research
Praxair Inc's (PX) fourth-quarter 2017 earnings surpassed the Zacks Consensus Estimate by 2.7% while revenues surpassed by 3.6%.
Praxair (PX) Secures Gas Supply Contract From EverDisplay
by Zacks Equity Research
Praxair, Inc. (PX) fortifies business in China on the back of recently-secured long-term gas supply deal from EverDisplayOptronics.
Should You Buy Praxair (PX) Ahead of Earnings?
by Zacks Equity Research
Praxair (PX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Will Demand & Contract Wins Aid Praxair's (PX) Q4 Earnings?
by Zacks Equity Research
Praxair's (PX) Q4 earnings are likely to gain from strengthening end-market demand and growing applications for industrial gases.
Praxair (PX) Extends Hydrogen Supply Contract With Motiva
by Zacks Equity Research
Increasing application of industrial gases in manufacturing, transportation, healthcare, food and beverages, and metal fabrication industries is beneficial for Praxair (PX).
Top Stock Reports for PepsiCo, Walgreens Boots & EOG Resources
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Walgreens Boots (WBA) and EOG Resources (EOG).
Can Sucampo Acquisition Turn Mallinckrodt Stock Around?
by Zacks Equity Research
Mallinckrodt (MNK) faced challenging business conditions in 2017 and the company is now looking to revive business with the recently announced Sucampo acquisition.
Mallinckrodt to Buy Sucampo for $1.2B to Diversify Portfolio
by Zacks Equity Research
Mallinckrodt (MNK) is all set to acquire Sucampo Pharmaceuticals to diversify its portfolio and counter the decline in sales of its largest drug, Acthar.
Here's Why You Should Hold on to Praxair (PX) Stock Now
by Zacks Equity Research
Praxair (PX) is well-poised to gain traction from solid contract wins, capital allocation policy and diversified business structure. Industry competition and rising costs remain issues.
Praxair Hikes Gas Prices to Cover High Energy & Labor Costs
by Zacks Equity Research
Praxair (PX) is poised to gain from increasing applications of industrial gases. Up to 15% hike in gas prices will help it recover increasing costs.
Why Is Praxair (PX) Up 4.5% Since the Last Earnings Report?
by Zacks Equity Research
Praxair (PX) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?
by Zacks Equity Research
Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.
Materials ETFs Head to Head: XLB vs. IYM
by Zacks Equity Research
Head to Head comparison of two financials ETFs, XLB and IYM.
Praxair (PX) Tops Q3 Earnings on Sales Growth, Ups '17 View
by Zacks Equity Research
Praxair's (PX) third-quarter 2017 adjusted earnings benefitted from higher sales in all segments but were adversely impacted by high costs and expenses.
Praxair Inc. (PX) Beats Q3 Earnings and Revenues
by Zacks Equity Research
Praxair Inc's (PX) third-quarter 2017 earnings surpassed the Zacks Consensus Estimate by 4.2% while revenues surpassed by 1.8%.
Key Predictions for Earnings Reports of APD, EMN & PX
by Zacks Equity Research
Chemical companies are expected to continue the earnings momentum in the September quarter as the fundamental driving factors remained firmly in place.
Will Regional Uncertainties Hurt Praxair's (PX) Q3 Earnings?
by Zacks Equity Research
Praxair's (PX) Q3 earnings are likely to gain from improving market conditions, benefits from contract wins and product launches in the prior quarter. Forex issues and stiff competition are concerns.